Patient Considerations When Selecting Disease-Modifying Therapy in Multiple Sclerosis

Released On
October 21, 2020

Expires On
October 21, 2021

Media Type

Completion Time
60 minutes

Neurology, Obstetrics & Gynecology, Pharmacy, Primary Care

Multiple Sclerosis

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and CMEology.

This activity is supported by educational grants from Biogen, Bristol Myers Squibb, and EMD Serono.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hour
  • Pharmacists — maximum of 1.0 ACPE Contact Hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of neurologists, advanced practice neurology clinicians, neurology nurses, pharmacists, and other members of the health care professional team involved in the care of patients with multiple sclerosis.

Program Overview

With more than a dozen disease-modifying therapies (DMTs) now available for multiple sclerosis (MS), treatment selection has become more complex. Clinicians need to know how and when to switch DMTs and ways to optimize outcomes in different situations, including pregnancy and breastfeeding. In this activity, expert faculty will discuss the latest options and best practices in DMT selection and how shared decision-making can be used to help patients meet their treatment goals. Management strategies and DMT considerations for pre-conception, pregnancy, and breastfeeding will also be explored. Two comic-style case scenarios and video commentary from 2 patients with MS will be presented to illustrate challenges encountered in clinical practice.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Evaluate the key considerations related to DMT selection
  • Employ optimal strategies for patient communication when starting or switching a DMT
  • Apply strategies for optimal selection and use of DMTs before, during, and after pregnancy
  • Define the elements of an effective shared decision-making process in DMT selection


Patricia K. Coyle, MD

Professor of Neurology and Vice Chair
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Patricia M. Melville, RN, MSN, ANP-BC, MSCN

Clinical Instructor
Department of Neurology
SUNY at Stony Brook
Stony Brook, NY

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and CMEology. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation

The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

The CMSC designates this enduring material for 1.0 continuing education nursing credit (1.0 in the area of pharmacology).

Pharmacists Credit

This knowledge-based activity (JA4008165-9999-20-056-H01-P) qualifies for 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit.

Disclosures of Conflicts of Interest

It is the policy of CMSC and CMEology to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence base and fair balance.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Patricia K. Coyle, MD

  • Consultant Fees: Accordant, Alexion, Biogen, EMD Serono, Genentech/Roche, GlaxoSmithKline, Mylan, Novartis, Sanofi-Genzyme, TG Therapeutics
  • Research Grants: Actelion, Alkermes, Corrona LLC, Genentech/Roche, MedDay, NINDS, Novartis

Patricia M. Melville, RN, MSN, NP-C, MSCN

  • Consultant Fees: Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme


Laurie Scudder, DNP, NP has served as both a planner and reviewer for this activity and has disclosed no relevant financial relationships.

June Halper, MSN, APN-C, MSCN, FAAN has served as both a planner and reviewer for this activity and has disclosed no relevant financial relationships.

CMEology planners have no relationships to disclose.

The staff at CMSC have disclosed no relevant financial relationships.

Instructions for Participation and Credit

There are no fees for participating in and receiving credit for this activity. During the period October 16, 2020 through October 16, 2021, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form. Passing grade is 70% and you are limited to 3 attempts.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Privacy Policy

Click here to view the CMEology privacy policy.

Contact Information

If you have any questions about this CE activity, please contact the CMSC at or CMEology at: